Claims
- 1. A compound of the formula ##STR27## wherein Q.sup.1 and the nitrogen taken together is a group of the formula >N--CH.sub.2 CH.sub.2 --S(O).sub.p -- or >N--CH.dbd.CH--S(O).sub.p --, p is the integer 0, 1 or 2, Ra is a phenyl, pyridyl or thienyl group which is optionally substituted by halogen, trifluoromethyl, nitro, lower alkyl or lower alkoxy, Rb and Rc together with the carbon atom denoted by .alpha. are a group of the formula >C.alpha.--S--CH.dbd.CH-- or >C.alpha.--CH.dbd.CH--S-- which is optionally substituted by halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro, amino or mono- or di(lower alkyl)amino, and the dotted line signifies an additional bond, Rd is a 5-membered, saturated, partially unsaturated or aromatic heterocycle including as the hetero ring member(s) an oxygen or sulfur atom or an amino or lower alkylamino group and optionally one or two nitrogen atoms which heterocycle is attached via a carbon atom and which is optionally substituted by one or two lower alkyl groups and optionally substituted by a C.sub.(3-6) -cycloalkyl, hydroxy, lower alkoxy, lower alkanoyloxy, lower hydroxyalkyl, lower alkoxyalkyl, lower alkanoyloxyalkyl, lower alkoxycarbonyl, lower alkanoyl, carbamoyl, mono- or di-(lower alkyl)carbamoyl, oxo or alkylenedioxy group, of a pharmaceutically acceptable acid addition salt of a compound of formula I which has one or more basic substituents.
- 2. A compound in accordance with claim 1, wherein Ra is phenyl which is optionally substituted by halogen, trifluoromethyl, nitro, lower alkyl or lower alkoxy.
- 3. A compound in accordance with claim 2, where Rd is a 5-membered aromatic heterocycle selected from the group consisting of 2-oxazolin-2-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 2-thiazolin-2-yl, 2-tetrahydrofuryl, and 2-thiazolyl.
- 4. A compound in accordance with claim 1, 5,6-dihydro-11-(3-methyl-1,2,4-oxadiazol-5-yl)-9-phenyl-8H-pyrido[1,2-d]-thieno[2,3-f][1,4]thiazepin-8-one.
- 5. A compound in accordance with claim 1, 5,6-dihydro-11-(3-methyl-1,2,4-oxadiazol-5-yl)-9-phenyl-8H-pyrido[1,2-d]-thieno[2,3-f][1,4]thiazepin-8-one 4-oxide.
- 6. A compound of the formula ##STR28## wherein Q.sup.5 and the nitrogen taken together are the group of the formula --CH.sub.2 --CHX.sup.1 --S(O).sub.p --and X.sup.1 is halogen, p is the integer 0, 1 or 2, Ra is a phenyl, pyridyl or thienyl group which is optionally substituted by halogen, trifluoromethyl, nitro, lower alkyl or lower alkoxy, Rb and Rc each, independently, are hydrogen, halogen, trifluoromethyl, lower alkyl, lower alkoxy or nitro and the dotted line signifies an additional bond, or Rb and Rc together with the carbon atom denoted by .alpha. are a group of the formula >C.alpha.--S--CH.dbd.CH-- or >C.alpha.--CH.dbd.CH--S-- which is optionally substituted by halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro, amino or mono- or di(lower alkyl)amino, and the dotted line signifies an additional bond, Rd is a 5-membered, saturated, partially unsaturated or aromatic heterocycle including as the hetero ring member(s) an oxygen or sulfur atom or an amino or lower alkylamino group and optionally one or two nitrogen atoms which heterocycle is attached via a carbon atom and which is optionally substituted by one or two lower alkyl groups and optionally substituted by a C.sub.(3-6) -cycloalkyl, hydroxy, lower alkoxy, lower alkanoyloxy, lower hydroxyalkyl, lower alkoxyalkyl, lower alkanoyloxyalkyl, lower alkoxycarbonyl, lower alkanoyl, carbamoyl, mono- or di(lower alkyl)carbamoyl, oxo or alkylenedioxy group.
- 7. A pharmaceutical composition comprising a compound of the formula ##STR29## wherein Q.sup.1 and the nitrogen taken together is a group of the formula >N--CH.sub.2 CH.sub.2 --S(O).sub.p -- or >N--CH.dbd.CH--S(O).sub.p --, p is the integer 0, 1 or 2, Ra is a phenyl, pyridyl or thienyl group which is optionally substituted by halogen, trifluoromethyl, nitro, lower alkyl or lower alkoxy, Rb and Rc together with the carbon atom denoted by .alpha. are a group of the formula >C.alpha.--S--CH.dbd.CH-- or >C.alpha.--CH.dbd.CH--S-- which is optionally substituted by halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro, amino or mono-or di(lower alkyl)amino, and the dotted line signifies an additional bond, Rd is a 5-membered, saturated, partially unsaturated or aromatic heterocycle including as the hetero ring member(s) an oxygen or sulfur atom or an amino or lower alkylamino group and optionally one or two nitrogen atoms which heterocycle is attached via a carbon atom and which is optionally substituted by one or two lower alkyl groups and optionally substituted by a C.sub.(3-6) -cycloaklyl, hydroxy, lower alkoxy, lower alkanoyloxy, lower hydroxyalkyl, lower alkoxyalkyl, lower alkanoyloxyalkyl, lower alkoxycarbonyl, lower alkanoyl, carbamoyl, mono- or di(lower alkyl)carbamoyl, oxo or alkylenedioxy group, or a pharmaceutically acceptable acid addition salt of a compound of formula I which has one or more basic substituents, and an inert pharmaceutical carrier.
- 8. A pharmaceutical composition in accordance with claim 7, wherein Ra is phenyl which is optionally substituted by halogen, trifluoromethyl, nitro, lower alkyl or lower alkoxy.
- 9. A pharmaceutical composition in accordance with claim 8, wherein Rd is a 5-membered aromatic heterocycle selected from the group consisting of 2-oxazolin-2-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 2-thiazolin-2-yl, 2-tetrahydrofuryl, and 2-thiazolyl.
- 10. A method of treating muscle tension, stress, insomnia, anxiety or convulsions which comprises administering to a host in requiring such treatment an effective amount of a compound of the formula. ##STR30## wherein Q.sup.1 and the nitrogen taken together is a group of the formula >N--CH.sub.2 CH.sub.2 --S(O).sub.p -- or >N--CH.dbd.CH--S(O).sub.p --, p is the integer 0, 1 or 2, Ra is a phenyl, pyridyl or thienyl group which is optionally substituted by halogen, trifluoromethyl, nitro, lower alkyl or lower alkoxy, Rb and Rc together with the carbon atom denoted by .alpha. are a group of the formula >C.alpha.--S--CH.dbd.CH-- or >C.alpha.--CH.dbd.CH--S-- which is optionally substituted by halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro, amino or mono- or di(lower alkyl)amino, and the dotted line signifies an additional bond, Rd is a 5-membered, saturated partially unsaturated or aromatic heterocycle including as the hetero ring member(s) an oxygen or sulfur atom or an amino or lower alkylamino group and optionally one or two nitrogen atoms which heterocycle is attached via a carbon atom and which is optionally substituted by one or two lower alkyl groups and optionally substituted by a C.sub.(3-6) -cycloalkyl, hydroxy, lower alkoxy, lower alkanoyloxy, lower hydroxyalkyl, lower alkoxyalkyl, lower alkanoyloxyalkyl, lower alkoxycarbonyl, lower alkanoyl, carbamoyl, mono- or di(lower alkyl)carbamoyl, oxo or alkylenedioxy group, or a pharmaceutically acceptable acid addition salt of a compound of formula I which has one or more basic substituents.
- 11. A method in accordance with claim 10 wherein Ra is phenyl which is optionally substituted by halogen, trifluoromethyl, nitro, lower alkyl or lower alkoxy.
- 12. A method in accordance with claim 11, wherein Rd is a 5-membered aromatic heterocycle selected from the group consisting of 2-oxazolin-2yl, 3-methyl-1,2,4-oxadiazol-5-yl, 2-thiazolin-2-yl, 2-tetrahydrofuryl, and 2-thiazolyl.
Priority Claims (2)
Number |
Date |
Country |
Kind |
5304/84 |
Nov 1984 |
CHX |
|
3836/85 |
Sep 1985 |
CHX |
|
Parent Case Info
This is a division of application Ser. No. 07/422,397, filed Oct. 16, 1989, now U.S. Pat. No. 5,036,066, which is a division of Ser. No. 07/141,022 filed Jan. 5, 1988, now U.S. Pat. No. 4,889,848, which is a division of Ser. No. 06/793,511 filed Oct. 31, 1985 now U.S. Pat. No. 4,735,940.
Foreign Referenced Citations (3)
Number |
Date |
Country |
0124935 |
Nov 1967 |
CSX |
183994 |
Jun 1986 |
EPX |
0199485 |
Oct 1986 |
EPX |
Non-Patent Literature Citations (2)
Entry |
Chemical Abstracts Service #CA107:134200, 1990. |
Liu et al., "Ormosia Alkaloids. VII. Total Synthesis of Ormosanine, Piptanthine, 18-Epiormosanine, and d,1-panamine", Can. J. Chem. vol. 54, No. 1, pp. 97-109 (Jan. 1, 1976). |
Divisions (3)
|
Number |
Date |
Country |
Parent |
422397 |
Oct 1989 |
|
Parent |
141022 |
Jan 1988 |
|
Parent |
793511 |
Oct 1985 |
|